(Q37996448)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Current status of targeted therapies in advanced gastric cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Gennaro Galizia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Fortunato Ciardiello

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Michele Orditura

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

3

Nicola Silvestris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

8

Giuseppe Colucci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Ferdinando De Vita

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Francesco Giuliani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Antonio Pizzolorusso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Giuseppe Santabarbara

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

23 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

16 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

S29-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Gastrointestinal cancer: recent developments in medical oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Bortezomib: a new pro-apoptotic agent in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.652616

10.1517/14728222.2011.652616

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22443228%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference